https://doi.org/10.4081/reumatismo.2009.4

Adherence to treatment of osteoporosis: an open question

Vol. 61 No. 1 (2009)
Abstract Views: 1218
PDF: 894
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

M. Varenna
office@pagepress.org
L. Sinigaglia
Effective drug therapies are available for a wide range of chronic medical conditions but adherence to medications is currently low with poor health outcomes. Evidences support that drug nonadherence is a universal problem more than a disease- and drug-specific problem. Although several methods have been proposed for the assessment of adherence, accurate measurement continues to be difficult and most studies produced inconsistent results on determinants of nonadherence. Osteoporosis is a chronic, asymptomatic illness before fracture, and poor adherence with antiresorptive medications is a significant problem in preventing its adverse consequences. Currently approved therapies for osteoporosis are effective and lower fracture risk, but about 50% of patients discontinues treatment within 12 months of initiation. Poor adherence has been associated with increased fracture risk and increased resource use and hospitalization. Causes of nonadherence to osteoporosis therapies are unknown. Some variables predictive of nonadherence have been found (older age, comorbidity, previous fractures, bone mineral density assessment, number of medications, institutionalisation) but explain only a small proportion of the variability of adherence. Patients may fail to remain on their medication for reasons that include inconvenience or complexity of dosing, high cost, side effects and lack of appreciation of the benefits of therapy. Potential solutions of poor adherence of osteoporosis may include a close monitoring of persistence and compliance, an improved relationship between physician and patient, and newer medications with extended dosing intervals.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

How to Cite

Varenna, M., & Sinigaglia, L. (2009). Adherence to treatment of osteoporosis: an open question. Reumatismo, 61(1), 4–9. https://doi.org/10.4081/reumatismo.2009.4

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.